Postoperative Readmission Is Associated With Worse Oncologic Outcomes After Radical Cystectomy for Bladder Cancer: A Multicenter Study of 3,972 Patients
Purpose: Radical cystectomy (RC) is associated with substantial postoperative morbidity, and unplanned readmission remains common despite advances in perioperative management. However, the association between postoperative readmission due to complications and oncologic outcomes after RC for bladder cancer has not been clearly defined. We evaluated the impact of postoperative readmission on overall survival (OS) and cancer-specific survival (CSS) after RC for bladder cancer.Materials and Methods: We retrospectively analyzed 3,972 patients who underwent RC for bladder cancer in a multicenter cohort. Postoperative readmission was defined as unplanned hospitalization within 90 days postsurgery due to surgery-related complications. Survival outcomes were assessed using the Kaplan-Meier method and compared using the log-rank test. Univariable and multivariable Cox proportional hazards regression analyses were performed to identify independent predictors of OS and CSS.Results: Among the study population, 916 patients (23.1%) experienced postoperative readmission. Baseline and perioperative characteristics were generally comparable between patients with and without readmission. Kaplan-Meier analyses demonstrated significantly worse OS and CSS among patients who experienced postoperative readmission (both log-rank p<0.001). In multivariable analyses adjusting for clinicopathological factors, postoperative readmission remained independently associated with worse OS (hazard ratio [HR], 1.654; 95% confidence interval [CI], 1.464–1.868; p<0.001) and CSS (HR, 1.761; 95% CI, 1.509–2.055; p<0.001).Conclusion: Postoperative readmission within 90 days after RC was independently associated with inferior long-term oncologic outcomes. These findings suggest the importance of strategies aimed at preventing postoperative complications and subsequent readmission.
Authors
- Tae Gyun Kwon (ORCID: https://orcid.org/0000-0002-4390-0952)
- Ho Kyung Seo (ORCID: https://orcid.org/0000-0003-2601-1093)
- Seok Ho Kang (ORCID: https://orcid.org/0000-0002-1524-5233)
- Bumsik Hong
- Geehyun Song
- Ja Hyeon Ku
- Wook Nam
- Seung-Hwan Jeong
- Hyun Hwan Sung
- Kyung Hwan Kim
- Won Sik Ham
- Tae-Hwan Kim
- Jong Ho Park
- Jieun Heo
- Wan Song
- Jungwon Park
- Sung Gu Kang
- Jong Kil Nam
- Jong Jin Oh
- Bumjin Lim
- Sangchul Lee
- Byong Chang Jeong
Institutions
- Ulsan College (KR)
- Yonsei University (KR)
- Korea University Medical Center (KR)
- Asan Medical Center (KR)
- Samsung Medical Center (KR)
- Seoul National University Hospital (KR)
- Seoul National University Bundang Hospital (KR)
- Kyungpook National University (KR)
- University of Ulsan (KR)
- Pusan National University Hospital (KR)
- National Cancer Center (KR)
- Gangneung Asan Hospital (KR)
- Pusan National University Yangsan Hospital (KR)
- Sungkyunkwan University (KR)
Publication Details
- Journal
- Journal of Urologic Oncology
- Published
- 2026-03-26
- DOI
- https://doi.org/10.22465/juo.255001240062
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00